Fig S1 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Fig S1. A. Treatment duration and clinical events for four subjects with clinical benefit. In the swimmer plot, patients are deceased at last follow-up unless indicated by the arrowhead. Abbreviations: LMS - leiomyosarcoma; UTUC - upper tract urothelial carcinoma; SCC - squamous cell carcinoma. B-C. Kaplan Meier curves for progression-free survival (B) and overall survival (C).